MARKET

CYTK

CYTK

Cytokinetics Inc
NASDAQ
60.60
+1.07
+1.80%
After Hours: 60.30 -0.3 -0.50% 18:09 05/20 EDT
OPEN
59.59
PREV CLOSE
59.53
HIGH
61.40
LOW
59.33
VOLUME
727.48K
TURNOVER
0
52 WEEK HIGH
110.25
52 WEEK LOW
25.98
MARKET CAP
6.35B
P/E (TTM)
-11.2164
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CYTK last week (0513-0517)?
Weekly Report · 21h ago
Cytokinetics CEO Blum says positioned to market heart drug aficamten by itself
Healthcare Cytokinetics CEO Blum says positioned to market heart drug aficamten by itself. CEO says company is poised to launch its hypertrophic cardiomyopathy drug on its own. The company has been the subject of takeover speculation in the past.
Seeking Alpha · 3d ago
'Amid Acquisition Speculation, Cytokinetics CEO Stresses Company Can Launch Heart Drug On Its Own' - STAT News
Cytokinetics faces pressure to sell itself to a large pharma company. CEO Robert Blum says the biotech can launch its first approved medication on its own. The company has positive late-stage results of a heart drug. Investors have questioned whether the company has the resources to compete.
Benzinga · 3d ago
CYTOKINETICS HOSTS MUSCLE BIOLOGY-FOCUSED RESEARCH SYMPOSIUM: CONTEMPORARY LANDSCAPES IN MUSCLE BIOLOGY
Reuters · 3d ago
Cytokinetics Board Changes and Stockholder Meeting Outcomes
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Alector (ALEC)
TipRanks · 4d ago
Buy Rating Justified by Cytokinetics’ Aficamten Favorable Trial Data and Safety Profile
TipRanks · 4d ago
CYTOKINETICS ANNOUNCES FIVE PRESENTATIONS RELATED TO AFICAMTEN AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2024
Reuters · 5d ago
More
About CYTK
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.

Webull offers Cytokinetics, Inc. stock information, including NASDAQ: CYTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYTK stock methods without spending real money on the virtual paper trading platform.